Your shopping cart is currently empty

BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally effective inhibitor of the BRG1/BRM enzyme domain. It exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis, and causing growth arrest. This compound is promising for research on BRG1/BRM-dependent malignancies, including hematologic cancers, prostate cancer, breast cancer, and Ewing's sarcoma.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally effective inhibitor of the BRG1/BRM enzyme domain. It exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis, and causing growth arrest. This compound is promising for research on BRG1/BRM-dependent malignancies, including hematologic cancers, prostate cancer, breast cancer, and Ewing's sarcoma. |
| Molecular Weight | 565.62 |
| Formula | C26H23N5O6S2 |
| Cas No. | 2468046-72-0 |
| Smiles | O=C(O)C1(C2=NC=CC(=C2)C3=CC=CC(=C3)C=4N=C(SC4)NC(=O)CNC(=O)C=5C=CN(C5)S(=O)(=O)C)CC1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.